TOKYO:4118

Foam Molded Product made from KANEKA Biodegradable Polymer Green PlanetTM Adopted for Sony’s Large-screen TV Cushioning Material

Retrieved on: 
Monday, April 22, 2024
Recycling, Sustainability, Consumer Electronics, Technology, Other Manufacturing, Environment, Other Transport, Packaging, Green Technology, Chemicals, Plastics, Transport, Logistics, Supply Chain Management, Manufacturing, Corporation, Kaneka, Seawater, Water, Sony, Television, Petroleum, Plastic, Soil, BRAVIA, Multimedia, CO2, Kaneka Corporation

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii; hereinafter "Kaneka")(TOKYO:4118) has announced that its "Green Planet foam molded product" using KANEKA Biodegradable Polymer Green PlanetTM (hereinafter "Green Planet") has been adopted by Sony Corporation (Headquarters: Minato-ku, Tokyo; hereinafter "Sony") as a cushioning material for its large-screen televisions.

Key Points: 
  • Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii; hereinafter "Kaneka")(TOKYO:4118) has announced that its "Green Planet foam molded product" using KANEKA Biodegradable Polymer Green PlanetTM (hereinafter "Green Planet") has been adopted by Sony Corporation (Headquarters: Minato-ku, Tokyo; hereinafter "Sony") as a cushioning material for its large-screen televisions.
  • To ensure shock resistance for large, heavy televisions during transportation, a certain level of strength and durability is required.
  • Using Sony's technical expertise in packaging design and Kaneka's material molding technology, the two companies conducted a series of technical verifications to realize the use of Green Planet's foam molded product as cushioning materials.
  • This is a world first*2 for Green Planet foam molded products to be used as cushioning materials for home electric appliances.

Kaneka Acquires Japan Medical Device Technology

Retrieved on: 
Wednesday, December 6, 2023
Surgery, Medical Devices, Health, Cardiology, Medical Supplies, Atherosclerosis, Human body, Restenosis, Kaneka, Research, Biliary tract, Artery, Extremities, Esophagus, Metal, Sirolimus, Coronary artery disease, Risk, Corporation, Multimedia, FIH, Duodenum, Thrombosis, Blood, Human, Trachea, Kaneka Corporation, Pharmaceutical industry

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.

Key Points: 
  • Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.
  • In particular, stenting*1 for the treatment of coronary artery diseases such as atherosclerosis has a market worth 30 billion yen in Japan, and Kaneka is aiming to expand its business in this area.
  • It is a medical device that widens tubular parts of the human body (blood vessels, trachea, esophagus, duodenum, colon, biliary tract, etc.)
  • [Japan Medical Device Technology Co., Ltd.]

KANEKA: “Development of Polymer Synthesis Technology by Microorganisms using CO2 as Direct Raw Material” selected as a NEDO Green Innovation Fund Project”

Retrieved on: 
Friday, March 31, 2023
Software, Research, Other Natural Resources, Data Management, Recycling, Technology, Natural Resources, Environment, Other Manufacturing, Green Technology, Science, Manufacturing, Carbon, Kaneka Corporation, Dionysus, JGC, NEDO, Breeding, Engineering, Gas, Construction, EPC, Ministry of Economy, Trade and Industry, Kobe City University of Foreign Studies, Fermentation, Multimedia, O2, Carbon neutrality, Strategic Innovation Fund, New energy, Ministry, Digital technology, JGC Holdings Corporation, Data analysis, Corporation, New Energy and Industrial Technology Development Organization, Knowledge, R, Robotics, CO2, Agriculture, Hyōgo Prefecture, H2, Shimadzu, Green Planet

During the project period (FY2023 to FY2030), the following three themes will be addressed.

Key Points: 
  • During the project period (FY2023 to FY2030), the following three themes will be addressed.
  • Development and demonstration of production technology using microorganisms capable of producing substances from CO2 (Kaneka, JGC HD, Shimadzu)
    Kaneka is the first company in the world to successfully commercialize KANEKA Biodegradable Polymer Green PlanetTM ("Green Planet"), which is produced by microorganisms from vegetable oil and other raw materials.
  • Bacchus aims to drastically shorten the breeding time of smart cells*3 by upgrading the breeding platform consolidating its proprietary technologies.
  • By utilizing its own digital technology, Bacchus will design cells optimized for gas fermentation and create a variety of species.

Kaneka expands GMP manufacturing capacity for mRNA in Kaneka Eurogentec S.A.

Retrieved on: 
Thursday, January 19, 2023
Biotechnology, Pharmaceutical, Other Manufacturing, Health, COVID-19, Infectious Diseases, Genetics, Manufacturing, Food and Drug Administration, Kaneka Corporation, Nucleotide, RNA transfection, Organic acid, DNA, Corporation, Animal, FDA, Bacteria, Vaccine, Infection, Protein, Cell division, Growth, Therapy, Escherichia coli, A-DNA, RNA, JPY, Research, Cancer, Good manufacturing practice, CDMO, Cosmetics, Health care, Peptide, Multimedia, Good, GMP, Fine chemical

Kaneka Eurogentec S.A. will grow as a leading company of biopharmaceutical CDMO*3, responding to the vigorous global demand for mRNA.

Key Points: 
  • Kaneka Eurogentec S.A. will grow as a leading company of biopharmaceutical CDMO*3, responding to the vigorous global demand for mRNA.
  • The demand for GMP manufacturing of mRNA will increase drastically with the active development of biopharmaceutical pipelines by pharmaceutical companies worldwide.
  • Kaneka Eurogentec S.A. is a CDMO for biopharmaceuticals inspected by the US FDA*4 and has world-class technology for producing plasmid DNA*5 and GMP manufacturing track records of over 25 years.
  • In addition, Kaneka Eurogentec S.A. has started GMP manufacturing services for mRNA since 2020, and this capacity expansion will be utilized to expand the CDMO business.

Kaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 Drug

Retrieved on: 
Tuesday, November 29, 2022
Chemicals, Plastics, Health, Infectious Diseases, Manufacturing, COVID-19, Pharmaceutical, Kaneka Corporation, COVID-19, Good manufacturing practice, Food and Drug Administration, Food, DNA, Ministry of Health and Medical Education, Ministry, Transport, Tablet, PCR, GMP, Infection, Corporation, Chūō-ku, Ministry of Health, Labour and Welfare, Pharmaceutical industry, Health, Shionogi

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) will manufacture and supply intermediates to Shionogi & Co., Ltd. (Headquarters: Chuo-ku, Osaka; Chief Executive Officer: Isao Teshirogi, Ph.D.) for use in Xocova*1 (Ensitrelvir Fumaric Acid) Tablets 125mg, a drug for the treatment of SARS-Cov-2 infection.

Key Points: 
  • Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) will manufacture and supply intermediates to Shionogi & Co., Ltd. (Headquarters: Chuo-ku, Osaka; Chief Executive Officer: Isao Teshirogi, Ph.D.) for use in Xocova*1 (Ensitrelvir Fumaric Acid) Tablets 125mg, a drug for the treatment of SARS-Cov-2 infection.
  • Shionogi recognized Kaneka for its long years of experience in manufacturing raw materials for medicines, and selected Kaneka as its main supplier for the drug's intermediates, which require GMP*2 management.
  • The two companies have worked closely together for clinical development, approval application, and establishment of mass production supply chain.
  • Kaneka will continue to improve its manufacturing systems and provide Shionogi with a stable supply of intermediates, playing a vital role in Shionogi's commercial supply chain.

Kaneka Launches New PCR Test Kit for Identifying the COVID-19 Omicron (BA.1) and "Stealth" Omicron (BA.2) Variants

Retrieved on: 
Wednesday, April 13, 2022
Biotechnology, Medical Supplies, Health, Infectious Diseases, Chemicals, Plastics, Hospitals, Manufacturing, Other Health, Gamma Omicron Delta Sigma, DNA, Infection, COVID-19, Research, API, PCR, Stealth, Kaneka Corporation, Severe acute respiratory syndrome coronavirus 2, Animal, Vaccine, Delta, Omicron

On March 31, Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) released KANEKA RT-PCR Kit SARS-CoV-2 (Omicron/Delta) ver.2, a real-time PCR test kit capable of simultaneously detecting the Omicron (BA.1), "Stealth" Omicron (BA.2), and Delta variants of COVID-19.

Key Points: 
  • On March 31, Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) released KANEKA RT-PCR Kit SARS-CoV-2 (Omicron/Delta) ver.2, a real-time PCR test kit capable of simultaneously detecting the Omicron (BA.1), "Stealth" Omicron (BA.2), and Delta variants of COVID-19.
  • This test kit uses a proprietary reagent developed using Kaneka's molecular testing-related technologies to detect the presence of three variants with a single PCR test.
  • Kaneka has already released the KANEKA Direct RT-PCR Kit SARS-CoV-2, an in-vitro diagnostic reagent that uses Kaneka's original sample processing technology to produce test results in less than an hour, KANEKA RT-PCR Kit SARS-CoV-2 (L452R/E484Q/E484K/N501Y), which can detect four variants simultaneously, and KANEKA RT-PCR Kit SARS-CoV-2 (Omicron/Delta) which can detect the Delta and Omicron variants of COVID-19.
  • These Kaneka products are being used at major sporting events and for pre-travel PCR testing, as well as in medical facilities and testing centers.

Kaneka: Price Revision of Photovoltaic Products

Retrieved on: 
Tuesday, March 1, 2022
Semiconductor, Chemicals, Plastics, Technology, Manufacturing, Alternative Energy, Energy, Hardware, Pressure, Silicon, Adoption, Corporation, Kaneka Corporation, Renewable energy

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) will raise the sales price of photovoltaic products by 20% or more for estimates issued from April 1st and onward.

Key Points: 
  • Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) will raise the sales price of photovoltaic products by 20% or more for estimates issued from April 1st and onward.
  • This will apply to all residential and non-residential photovoltaic products.
  • The price of silicon wafers, the main material used in the photovoltaic manufacturing, has risen dramatically due to the global silicon shortage.
  • However, the measures reached the limit and thus Kaneka could not help but to make price revision to steadily provide photovoltaic products to the market.